Cargando…
Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
Only half of patients with relapsed B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) currently survive with standard treatment protocols. Predicting individual patient responses to defined drugs prior to application would help therapy stratification and could improve survival. With the purp...
Autores principales: | Gauert, Anton, Olk, Nadine, Pimentel-Gutiérrez, Helia, Astrahantseff, Kathy, Jensen, Lasse D., Cao, Yihai, Eggert, Angelika, Eckert, Cornelia, Hagemann, Anja I.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408814/ https://www.ncbi.nlm.nih.gov/pubmed/32668722 http://dx.doi.org/10.3390/cancers12071883 |
Ejemplares similares
-
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation
por: Lázaro-Navarro, Juan, et al.
Publicado: (2021) -
A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
por: Grunewald, Laura, et al.
Publicado: (2021) -
Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
por: Arlt, Birte, et al.
Publicado: (2021) -
Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
por: Wu, Zhiyang, et al.
Publicado: (2021) -
Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
por: Erarslan‐Uysal, Büşra, et al.
Publicado: (2020)